nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

PURPOSE: The global Phase III MPACT trial demonstrated superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone as first-line treatment for metastatic pancreatic cancer. Region was a randomization stratification factor in the MPACT trial. This subgroup analysis of MPACT examined e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295788/
https://www.ncbi.nlm.nih.gov/pubmed/28203092
http://dx.doi.org/10.2147/OTT.S124097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295788/
https://www.ncbi.nlm.nih.gov/pubmed/28203092
http://dx.doi.org/10.2147/OTT.S124097

Ejemplares similares